 SAN DIEGO, Jan. 19, 2021 GLOBE NEWSWIRE -- Histogen Inc. NASDAQ: HSTO, a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function today announced that the U.S. Food and Drug Administration FDA has verbally notified the company that it has additional questions about the companys Investigational New Drug IND application package for the planned Phase 12 clinical trial of HST-003, which is intended to evaluate the safety and efficacy of human extracellular matrix hECM:HST-003 implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure. 